Introduction:

This study reports the long-term outcomes in patients affected by uveal melanoma (UM) treated with ruthenium-106 (¹⁰⁶Ru) plaque bra­chytherapy (BT).

Material and methods:

From May 2005 to January 2024, 127 patients (median age: 69 years, range: 32–90 years) affected by small and medium UM were treated with ¹⁰⁶Ru plaque BT at the University Hospital of Pisa. All the patients were treated with ¹⁰⁶Ru plaque BT with a prescription dose of 110 Gy to the tumor apex.

Results:

Inclusion criteria comprised Eastern Cooperative Oncology Group performance status ≤ 2, life expectancy > 6 months, and tumor thickness ≤ 6 mm and/or diameter ≤ 16 mm. The 5-year rate of local control, progression-free survival, metastasis-free survival, and overall survival were 95.2%, 85.4%, 93.0%, and 95.9%, respectively. Local progression was recorded in nine patients (7.1%): two of them (1.6%) had also distant metastasis. Seven patients were retreated with photon beam and one patient with proton beam stereotactic radiosurgery; one patient was retreated with ¹²⁵I plaque BT. Only one patient underwent enucleation for large local progression after about 10 years. Thirty-four patients (26.8%) had one or more acute and late toxicities. No grade 4 acute or late toxicity was reported.

Conclusions:

This study suggests that ¹⁰⁶Ru plaque BT is a successful and well-tolerated radiotherapy technique in the management of UM.